Our products

Topical (via the skin) pain-control products for humans and animals

Auxesis Pharma develops topical pain-control medicines that act directly in the skin.

Our products are designed to deliver fast, targeted effect for insect bites, skin irritation, stinging sensations and localized pain — without burdening the rest of the body.

Our portfolio is based on a stable, liquid form of acetylsalicylic acid and is the result of Swedish research and development: ASA.P® for humans and CoxyPet® for animals.

ASA.P application

ASA.P® — for humans

ASA.P® is our first product line for humans. It is designed for fast pain-control effect in skin pain that can occur from insect bites, jellyfish stings, eczema, herpes, irritation, sunburn and other localized skin conditions.


ASA.P COX-2 (Cyclooxygenase-2) is an enzyme that plays a central role in inflammatory processes in the body, leading to pain, redness, swelling and heat.

CoxyPet fur

CoxyPet® — for animals

CoxyPet® is our veterinary portfolio of topical medicines developed to treat pain and irritation in animals locally. We aim to reduce the need for antibiotics through effective localized pain control in animals, offering a safer and more sustainable alternative to systemic treatments.


As in humans, topical treatment can provide fast pain-control effect without systemic burden.

Broad areas of use.

Our technology effectively addresses a range of common yet painful conditions.

Different types of skin pain:

Mosquito bites

Fast effect against itching, swelling and irritation.

Jellyfish stings

Reduces stinging and redness and supports skin recovery.

Pets

Fast effect for dogs and cats for minor injuries, irritation or inflammation.

Wasp stings

Reduces pain, burning sensation and local inflammatory reactions.

Young children

Young children can experience irritation and pain from e.g. common childhood rashes or bites, which can be uncomfortable.

Livestock

Topical pain-control effect for local injuries, insect bites and skin irritation.

2025–Formulation validation

The formulation is validated for solubility, permeability and stability.

2026–Regulator & clinical studies

Submission to the Swedish Medical Products Agency for approval of clinical trials for ASA.P®. Trials begin in the first half of 2026 and conclude during 2026.

2027–2028–Market introduction

Launch as the world’s first OTC, fast-acting medicine that removes pain. Expansion first in Sweden and then in the EU during 2028.

2029–Animal market launch

Launch for the veterinary market under the CoxyPet® brand, protected in over 50 countries.

2030–New medicines

New skin medicine based on ASA.P® for the cosmetic market addressing various skin changes.

New products launched at a rapid pace

Our product strategy is to develop innovative medicines that quickly remove pain and irritation in the skin for both humans and animals, based on proprietary patents.

Building on our patent, Auxesis also develops prescription medicines and cosmetic products that are accessible to consumers and professional groups. One area is cosmeceuticals — cosmetics with medical benefits.

More about upcoming products
Skin-focused product development

Frequently asked questions

General information about Auxesis Pharma’s products and technology.

ASA.P® is based on patented technology that acts locally and quickly on the pain signal in the skin, without being systemic or hormone-based.

Yes, the technology can also be applied in animal health and cosmetic products with medical benefits.

Products are developed with high safety requirements and are intended to be gentle for both humans and animals.

Classification depends on the use case, including over-the-counter medicines and veterinary products.